Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Guodong Li

Pain Medicine Beverly Hills, CA Medical Doctor

NPI 1588988224 CMS profile 1370817

130 S Hamel Dr., Beverly Hills, CA 90211

Open in the dashboard

General payments

$3,380

84 records reported · program years 2019–2023

Research payments

$820

Paid to them · 1 record reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Guodong Li of Beverly Hills, CA is reported in the CMS Open Payments database as having received $3,380 across 84 general payments and $820 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $110 1
2022 General $19 1
2021 General $175 3
2020 General $173 7
2020 Research $820 1
2019 General $2,903 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guodong Li
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Guodong Li were reported at $0. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Guodong Li Pain Medicine median Middle half National median
2019 $2,903 $506 $144–$1,566 $163
2020 $173 $315 $96–$934 $114
2021 $175 $452 $134–$1,237 $132
2022 $19 $475 $124–$1,407 $149
2023 $110 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $0 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic USA, Inc. $2,420 32 payments
  2. Collegium Pharmaceutical, Inc. $253 19 payments
  3. Daiichi Sankyo Inc. $156 10 payments
  4. Medtronic, Inc. $139 1 payment
  5. Sentynl Therapeutics, Inc. $131 9 payments
  6. Nevro Corp. $110 1 payment
  7. Abbott Laboratories $55 3 payments
  8. Amgen Inc. $31 1 payment
  9. ERMI Inc. $20 1 payment
  10. Scilex Pharmaceuticals Inc. $19 1 payment
  11. Other $46 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,946 80 payments
  2. Consulting Fee $820 1 payment
  3. Travel and Lodging $614 3 payments
Products named General payments · program years 2019–2023
  1. INTELLIS $714 18 payments
  2. KYPHON Balloon Kyphoplasty $639 5 payments
  3. XTAMPZA $253 19 payments
  4. Morphabond ER $147 9 payments
  5. Vanta $139 1 payment
  6. Levorphanol Tartrate $131 9 payments
  7. Senza $110 1 payment
  8. N'VISION $94 4 payments
  9. TARGETSTIM $85 1 payment
  10. SYNCHROMED $68 3 payments
  11. Other $240 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Medtronic USA, Inc. $820 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,294

Median for Pain Management: 951

Drug cost

$34,523

Median for Pain Management: $26,034

Branded share of claims

30%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 14 $17,546
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 260 $6,106
Gabapentin Generic 317 $4,393
Pregabalin Generic 96 $1,699
Oxycodone Hcl Generic 162 $1,130
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 62 $817
Fentanyl Generic 13 $648
Cyclobenzaprine Hcl Generic 37 $306
Duloxetine Hcl Generic 28 $306
Morphine Sulfate Er Morphine Sulfate Brand 16 $283

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$572,333

Medicare's payments for the services billed

Medicare patients

487

Average age 74

Services billed

6,115

296 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 58%
Depression 54%
Diabetes 46%
Chronic kidney disease 44%
Heart failure 42%
Osteoporosis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record